Biomarkers that predict who among recently Mycobacterium tuberculosis (MTB)-exposed
individuals will progress to active tuberculosis are urgently needed. Intracellular microRNAs …

Background The optimal diagnosis and treatment of tuberculosis (TB) are challenging due to
underdiagnosis and inadequate treatment monitoring. Lipid-related genes are crucial …

Poor sensitivity of sputum conversion for monitoring tuberculosis (TB) treatment that makes
identification of a non-sputum-based biomarker is urgently needed. Monitoring biomarkers …

Untreated active tuberculosis (TB) has a very high long-term mortality. Treatment of TB
reduces mortality dramatically and should maximize cure, preventing ongoing transmission …

Advances in discovery and validation of diagnostic, prognostic and treatment-monitoring
transcriptomic signatures of tuberculosis (TB) disease could accelerate the goal to end TB …

Background To facilitate better discrimination between patients with active tuberculosis (TB)
and latent TB infection (LTBI), whole blood transcriptomic studies have been performed to …

After extensive exposure to Mycobacterium tuberculosis (Mtb), most individuals acquire
latent Mtb infection (LTBI) defined by a positive tuberculin skin test (TST) or interferon-γ …

Natural history studies of tuberculosis (TB) have revealed a spectrum of clinical outcomes
after exposure to Mycobacterium tuberculosi s, the cause of TB. Not all individuals exposed …

To achieve the ambitious targets for tuberculosis (TB) prevention, care, and control stated by
the End TB Strategy, new health care strategies, diagnostic tools are warranted. Host …

Annually, approximately 10 million people are diagnosed with active tuberculosis (TB), and
1.4 million die of the disease. If left untreated, each person with active TB will infect 10–15 …